Seagen Inc. is a biotechnology company focused on developing and commercializing innovative therapies for cancer treatment. The company's mission is to improve the lives of patients by harnessing the power of antibody-drug conjugates and other targeted therapies. Seagen Inc. employs a strategy centered on advancing its robust pipeline of oncology products through rigorous research and clinical trials, aiming to address unmet medical needs in various cancer types. With a commitment to scientific excellence and collaboration, Seagen Inc. strives to lead in the field of cancer therapeutics, ultimately enhancing patient outcomes and quality of life.

SEAGEN INC

Seagen is making notable strides in the oncology sector, particularly through its recent acquisition by Pfizer. In 2024, Seagen generated $3.4 billion in sales, reflecting a robust 38% increase on a proforma basis. This surge has been pivotal for Pfizer, with the oncology segment now representing approximately 25% of its...

Seagen's $3.4 Billion Contribution Boosts Pfizer's Oncology Revenue Amid Patent Expirations and Declining COVID Sales

Seagen's impressive $3.4 billion sales in 2024 marks a significant boost for Pfizer's oncology revenue, now comprising 25% of its total. As both companies navigate challenges and aim for ambitious growth, can Seagen maintain its momentum in an evolving oncology landscape?